Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine for generalized anxiety disorder and social phobia
ACTRN12615000617561Phase 2Completed
- Sponsor
- University of Otago
- Start
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ketamine in generalized anxiety disorder (GAD) and Social Anxiety Disorder (SAD) (5 arms), sponsored by University of Otago. Primary endpoint: Change in anxiety rating scales. Started Nov 2015; status: completed.
02
Drugs
ketamine
03
Conditions
generalized anxiety disorder (GAD)Social Anxiety Disorder (SAD)
Beyond the preview
Go deeper on ACTRN12615000617561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12615000617561.